Bone Therapeutics Raises $10.4M To Speed Phase III Cell Therapy Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgium's Bone Therapeutics raises $10.4 million in a Series D financing to fund a Phase III study of its lead product, an osteoblast cell therapy for osteonecrosis of the hip and non-union bone fractures.
You may also be interested in...
Financings Of The Fortnight Expects An Increase In Life Sciences IPOs In 2013
Plus news of recent financings by the Pfizer animal health spin-out Zoetis, Bone Therapeutics, Ariad Pharmaceuticals and Foresight Capital Management.
Pharmacovigilance Feeds EMA’s Transparency Drive
The scandal surrounding the withdrawal of Servier’s diabetes drug Mediator (benfluorex) continues to rock the French medical establishment, but it also has drawn attention to the issue of regulators' transparency more broadly – including at the European Medicines Agency.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.